Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

Autor: Marc Schwartz, Suzanne C. O'Neill, Nandini Selvam, Claudine Isaacs, Chunfu Liu, Vanessa B. Sheppard, Filipa Lynce, Calvin Chao, Arnold L. Potosky, Yingjun Zhou, Deena Graham
Rok vydání: 2017
Předmět:
Adult
Endocrine therapy
0301 basic medicine
Oncology
medicine.medical_specialty
medicine.medical_treatment
Breast Neoplasms
Kaplan-Meier Estimate
lcsh:RC254-282
Medication Adherence
Young Adult
03 medical and health sciences
Breast cancer
0302 clinical medicine
Recurrence
Risk Factors
Surgical oncology
Survivorship curve
Internal medicine
Odds Ratio
medicine
Humans
Breast imaging
Genomic testing
Aged
Neoplasm Staging
Aged
80 and over
Medicine(all)
Chemotherapy
medicine.diagnostic_test
business.industry
Gene Expression Profiling
Age Factors
Cancer
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
3. Good health
Discontinuation
030104 developmental biology
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Cohort
Female
Oncotype DX
business
Research Article
Zdroj: Breast Cancer Research : BCR
Breast Cancer Research, Vol 19, Iss 1, Pp 1-13 (2017)
ISSN: 1465-542X
Popis: Background Aside from chemotherapy utilization, limited data are available on the relationship between gene expression profiling (GEP) testing and breast cancer care. We assessed the relationship between GEP testing and additional variables and the outcomes of endocrine therapy initiation, discontinuation and adherence, and breast imaging exams in women under age 65 years. Methods Data from five state cancer registries were linked with claims data and GEP results. We assessed variables associated with survivorship care outcomes in an incident cohort of 5014 commercially insured women under age 65 years, newly diagnosed with stage I or II hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2) non-positive breast cancer from 2006 to 2010. Results Among tested women, those with high Oncotype DX® Breast Recurrence Score® (RS) were significantly less likely to initiate endocrine therapy than women with low RS tumors (OR 0.40 (95% CI 0.20 to 0.81); P = 0.01). Among all test-eligible women, receipt of Oncotype DX testing was associated with a greater likelihood of endocrine therapy initiation (OR 2.48 (95% CI 2.03 to 3.04); P
Databáze: OpenAIRE
Externí odkaz: